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Abstract 31 
 32 
During industrialization, humans have been exposed to increasing numbers of foreign 33 
chemicals.  Failure of the immune system to tolerate drugs, cosmetics and other skin products 34 
causes allergic contact dermatitis, a T cell-mediated disease with rising prevalence.   Models 35 
of αβ T cell response emphasize T cell receptor (TCR) contact with peptide-MHC complexes, 36 
but this model cannot readily explain activation by most contact dermatitis allergens, which 37 
are non-peptidic molecules.  We tested whether CD1a, an abundant MHC I-like protein in human 38 
skin, mediates contact allergen recognition. Using human αβ T cell clones to screen clinically 39 
important allergens present in skin patch testing kits, we identified responses to balsam of 40 
Peru, a tree oil widely used in cosmetics and toothpaste.  Additional purification and structure-41 
guided compound screening identified benzyl benzoate, benzyl cinnamate, farnesol and 42 
coenzyme Q and other stimulants of T cells. Certain general chemical features controlled 43 
response: small size, extreme hydrophobicity and chemical constraint from rings and 44 
unsaturations.  Unlike lipid antigens that protrude to form epitopes and contact TCRs, the small 45 
size of farnesol allows sequestration deeply within CD1a, where it displaces self lipids and 46 
unmasks the CD1a surface.  These studies identify molecular connections between CD1a and 47 
hypersensitivity to consumer products, defining a mechanism that could plausibly explain the 48 
many known T cell responses to oily substances.  49 
  50 






The human immune system evolved to respond to foreign microbial antigens, but must also tolerate 55 
foreign compounds present in the environment, such as plants and foods. Over the past two centuries, 56 
industrialization has introduced the widespread use of chemical extraction techniques and synthetic 57 
chemistry methods.  Industrial development has greatly increased the range of synthetic or purified 58 
botanical compounds to which humans are commonly exposed through pollution, or the intentional 59 
use of drugs, fragrances, cosmetics and other consumer products, especially those applied at high 60 
concentrations directly on the skin. Accordingly, the incidence of contact dermatitis has risen, 61 
especially in industrialized countries (1).   Lifetime incidence currently exceeds 50%, making contact 62 
dermatitis the most common occupational skin disease (2).  The essential pathophysiological feature 63 
of contact dermatitis is the allergen-specific nature of immune hypersensitivity reactions. Diagnosis 64 
relies on identifying the specific allergens to which a patient was exposed.  Physicians measure local 65 
skin inflammation to a grid network of allergen patches applied to the skin as a diagnostic test. The 66 
mainstay of treatment is avoidance of exposure to named allergens. 67 
    Considerable evidence documents a role for  T cells in contact dermatitis, which is caused 68 
by delayed type hypersensitivity reactions. Gell and Coombs defined Type IV reactions as 'delayed 69 
type' hypersensitivity because they appear after 72 hours.  Type IV reactions are T cell-mediated and 70 
are worsened after repeated exposure to allergens (3). During the sensitization phase, naive T cells 71 
are activated in a process that involves Langerhans cells and dermal dendritic cells (2). In the elicitation 72 
phase, T cells cause inflammatory manifestations in the skin.  Biologists' views of T cell response are 73 
strongly influenced by the known mechanisms by which T cell antigen receptors (TCRs) recognize 74 
peptide antigens bound to major histocompatibility complex (MHC) I and MHC II proteins (4-6). Yet, 75 
most known contact allergens are non-peptidic small molecules, cations or metals that are typically 76 
delivered to skin as drugs, oils, cosmetics, skin creams or fragrances (1, 2). Thus, the chemical nature 77 
of contact allergens does not match the chemical structures of most antigens commonly recognized 78 
within the TCR-peptide-MHC axis. 79 
This apparent disconnect, which represents a core question regarding the origin of delayed 80 
type hypersensitivity, might be explained if MHC proteins use atypical binding interactions to display 81 
non-peptidic antigens to TCRs. For example, the anti-retroviral drug abacavir binds within the HLA-82 
B*57:01 groove to alter the seating of self-peptides, creating neo-self epitopes (7).  Similarly, the MHC 83 
class II protein encoded by HLA-DP2,  can bind beryllium, thereby plausibly altering the MHC-peptide 84 
complex shape to enable binding of an autoreactive TCR (8).  Here, autoimmune response to non-85 
peptidic compounds still involves peptides in some way, and is linked to a specific HLA-allomorph that 86 
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uses a defined structural mechanism. A second general model is that non-peptidic allergens form 87 
covalent bonds with peptides in vivo. Such 'haptenation' reactions might create hybrid molecules with 88 
peptide-based MHC binding moieties and TCR epitopes formed from the haptenizing drug or chemical. 89 
This concept derived from Landsteiner's landmark studies with 2,4-dinitrophenols (9) and evolved into 90 
broader predictions that drugs could haptenate peptides or innate receptors (10).  Some evidence 91 
indicates that drugs can generate immune hypersensitivity reactions via haptenation.  For example, 92 
sulfamethoxazole, lidocaine, penicillins, lamotrigine, carbamazepine, p-phenylendiamine or 93 
gadolinium can bind peptides, MHC proteins or TCRs (11-16).  Although the haptenation hypothesis 94 
is broadly taught to physicians, the extent to which it accounts for the larger spectrum of contact 95 
allergens remains unknown (17).   96 
Both of these models derive from the premise that T cell responses are mediated by MHC 97 
encoded proteins and emphasize atypical modes of peptide presentation.   Putting aside this premise, 98 
we tested a straightforward model whereby drugs and other non-peptidic contact allergens are 99 
presented by a system that evolved to present non-peptidic antigens to T cells (18).  CD1 proteins are 100 
MHC I-like molecules that fold to form an antigen binding cleft comprised of two pockets, A' and F', 101 
which are larger and more hydrophobic than the clefts present in MHC I and MHC II proteins (19, 20).  102 
Most published studies of human CD1 proteins (CD1a, CD1b, CD1c and CD1d) emphasize display of 103 
amphipathic membrane phospholipids and sphingolipids.  The alkyl chains bind within and fill up the 104 
cleft of CD1, and the polar head groups, comprised of carbohydrates or phosphate esters, protrude 105 
through a small portal (F' portal) to lie on the outer surface of CD1, where they are presented to TCRs 106 
(21).    107 
 Whereas most known antigens are amphipathic lipids, some evidence suggests that CD1 108 
proteins mediate recognition of non-lipidic, drug-like molecules.  For example, CD1d mediates T cell 109 
response to phenyl pentamethyldihydrobenzofuran sulfonates (PPBFs) (22), and chemically reactive 110 
small molecules can influence CD1-restricted T cell response by an unknown mechanism that might 111 
involve induced lipid autoantigen synthesis (23).  PPBFs lack aliphatic hydrocarbon chains that define 112 
lipids, and they are instead ringed, sulfated small molecules that chemically resemble allergenic drugs, 113 
such sulfonamide antibiotics and furosemide. However, PPBF antigens are much smaller than the 114 
known volume of CD1d cleft. Unlike amphipathic lipids, they lack a defined lipid anchor and hydrophilic 115 
head group (22), raising questions about how PPBFs could bind within CD1d and yet protrude in some 116 
way for TCR contact.   117 
 Among human CD1 isoforms, we focused on CD1a because it is abundantly expressed on 118 
epidermal Langerhans cells and dermal dendritic cells, which are implicated in contact dermatitis (24). 119 
Also, CD1a-autoreactive T cells home to the skin, and polyclonal autoreactive T cells derived from 120 
blood and skin show higher responses to CD1a as compared to other CD1 proteins (25, 26).  In 121 
addition, surface CD1a proteins can rapidly capture extracellular antigens using mechanisms that do 122 
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not require complex mechanisms of antigen processing within the endosomal network (27, 28).  123 
Recently, transfer of human CD1a into mice (29) was found to augment intradermal T cell responses 124 
to the natural, plant-derived compound, urushiol (30).  Actual CD1a-mediated T cell responses to 125 
commonly used drugs or contact allergens in consumer goods are, to our knowledge, unknown. 126 
 As a screen for the most common and clinically important contact dermatitis antigens, we 127 
tested for human T cell response to compounds embedded in the thin-layer rapid use epicutaneous 128 
(T.R.U.E.) test (or Truetest), which is broadly used in dermatology and allergy clinics to screen patients 129 
for contact dermatitis allergens that are most commonly encountered in medical practice. This 130 
approach identified a human T cell response to a tree oil-derived contact allergen known as balsam of 131 
Peru. Larger scale screens defined the general chemical requirements for a T cell response to oily 132 
substances and discovered additional contact allergens presented by CD1a, including farnesol.  The 133 
crystal structure of the CD1a-farnesol complex and study of the self lipids bound to CD1a provided 134 
evidence for a molecular mechanism for recognition of a contact allergen, explaining how small 135 
antigens sequestered fully within CD1a can lead to T cell response through absence of interference 136 
with CD1-TCR contact.    137 
 138 
 139 
Results and Discussion 140 
 141 
Balsam of Peru binds CD1a and activates T cells 142 
 To determine if CD1a can present contact allergens to T cells, we initially used the CD1a-143 
restricted -T cell line known as BC2 for testing response to the T.R.U.E. test panel 1 (Truetest 1) 144 
(Fig. S1).   BC2 is a T cell line derived from peripheral blood T cells of a blood bank donor, and has 145 
previously been shown to be activated by CD1a loaded with small hydrophobic self lipids (31). 146 
Normally, the Truetest panel consists of compounds arrayed on sterile matrix, which is placed on 147 
patient skin.  Localized erythema occurring in vivo on skin 2-5 days after exposure is considered a 148 
positive test, allowing allergen identification based on position in the grid. For testing in vitro, individual 149 
allergen patches and untreated patch matrix (control patch) were cut apart with sterile technique.  150 
Patches were soaked in media and removed (soaking method) or inserted into wells to contact (contact 151 
method) CD1a-transfected K562 (K562-CD1a) antigen presenting cells (APCs). We saw a modest 152 
response to K562-CD1a in the absence of added patch material using interferon-ELISA, as expected 153 
based on the known CD1a autoreactivity of the BC2 T cell line (Fig. S1a).  154 
 Compared to the control patch, most of the antigen-containing patches, including nickel, 155 
potassium dichromate, colophony, lanolin and paraben, showed no effect.  A combination of molecules 156 
known as 'fragrance mix 1' showed slight suppression of cytokine release, consistent with toxicity to 157 
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cells (Fig. S1a).   Cobalt, neomycin and ethylenediamine dihydrochloride showed small increases in 158 
interferon- at some doses tested, but not reproducibly in subsequent assays (not shown).  In contrast, 159 
balsam of Peru showed a significant response above background (Fig. S1a), which also repeated in 160 
subsequent assays (Figs. S1b, Fig. 1a). Response to balsam of Peru was not seen with patch soaking 161 
(Fig. S1b), indicating that the stimulatory factor(s) was not physically released from the patch.  Overall, 162 
the screen suggested a T cell response to balsam of Peru embedded in Truetest patches, leading to 163 
focused studies of this natural botanical extract.  164 
Balsam of Peru is a resin from the South American tree, Myroxylon balsamum, which has a 165 
vanilla scent and is used as a fragrance and flavor in many personal care products such as skin creams 166 
and toothpaste.  Balsam of Peru is a common contact allergen seen in medical practice, where it 167 
causes severe skin rash in allergic individuals (32, 33). We tested balsam of Peru extract and oily 168 
substances derived therefrom, which is known as balsam of Peru oil.  Both preparations are commonly 169 
used in consumer products.  BC2 was activated by both preparations, establishing a T cell dose 170 
response to a common botanical extract used in consumer goods (Fig. 1a). 171 
Given the unusual chemical nature of oily substances found in Balsam of Peru oil, we 172 
considered candidate mechanisms of T cell activation other than antigen display by CD1a.   In theory, 173 
compounds might undergo peptide haptenation reactions for presentation by MHC proteins, but this 174 
possibility was less favored since K562 cells express very low or undetectable MHC I and MHC II (25).   175 
Oily mixtures might influence cellular lipid production (23) or contain mitogens that cross-link CD3 176 
complexes or broadly activate lymphocytes via TCR-independent mechanisms (34). To determine the 177 
cellular and molecular mechanisms of T cell stimulation, we measured T cell activation by K562 APCs 178 
and by biotinylated CD1a proteins bound to avidin-coated plates.  As assessed with anti-CD1a 179 
blocking antibodies and K562 cells lacking CD1a, CD1a was required for the BC2 response to crude 180 
balsam of Peru and oils derived therefrom (Fig. 1b-c). Treating plate bound CD1a protein with balsam 181 
of Peru was sufficient to activate the BC2 response, albeit at higher doses than with antigen in the 182 
presence CD1a-expressing cells (Fig. 1c). Thus, APCs facilitate some aspect of T cell response, but 183 
clear activation in APC-free systems ruled out that antigen processing is required.  As a specificity 184 
control, BC2 did not respond structurally unrelated lipid, sphingomyelin, which is a known ligand for 185 
CD1a (Fig. 1d) (35). These results were most consistent with CD1a forming complexes with some 186 
molecule in these antigen preparations. Further specificity controls showed that Balsam of Peru 187 
preparations did not activate a CD1a-restricted T cell clone, CD8-2, that recognizes CD1a presenting 188 
a mycobacterial antigen (18, 36) (Fig. 1d).  This finding, along with the absolute requirement for CD1a 189 
in all recognition events, strongly indicated these substances are not mitogens.  However, both balsam 190 
of Peru and balsam of Peru oil did activate another CD1a-autoreactive T cell line, Bgp (31). This 191 
indicates that balsam of Peru response was not limited to the BC2 T cell line (Fig. 1e).  192 
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 193 
Chemical composition of balsam of Peru 194 
 Next, we sought to pinpoint chemical structures of the antigenic substances.  Balsam of Peru 195 
is a complex botanical extract, with the most abundant components previously reported to be benzyl 196 
cinnamate and benzyl benzoate (37). Silica thin-layer chromatography (TLC) showed that crude 197 
balsam of Peru contained hydrophilic compounds that remained near the origin, as well as two dark 198 
spots that co-migrate with synthetic benzyl benzoate and benzyl cinnamate standards (Fig. 2a). As 199 
expected, oils extracted from balsam of Peru lacked the hydrophilic compounds that adhered at the 200 
origin.  Balsam of Peru oil generated one dark spot that co-migrated with benzyl benzoate. More 201 
sensitive methods of positive mode nano-electrospray ionization mass spectrometry (nano-ESI-MS) 202 
(Fig. 2b) detected sodium adducts [M+Na]+ of benzyl cinnamate (m/z 261.3) and benzyl benzoate 203 
(m/z 235.3) in both preparations.  The signal for benzyl benzoate was ~10-fold stronger than for benzyl 204 
cinnamate in balsam of Peru oil. Thus, benzyl cinnamate was present in both preparations, but its 205 
concentration was below the threshold of detection by TLC.  206 
 207 
Benzyl cinnamate and benzyl benzoate are CD1a-presented antigens 208 
False positive results from trace contaminants in natural preparations occur, so we tested 209 
whether benzyl benzoate and benzyl cinnamate, provided as purified synthetic molecules, activated 210 
CD1a-restricted T cells.  We observed T cell activation in response to both synthetic molecules, and 211 
the response was dependent on pre-coating the plate with CD1a.  We observed a stronger and more 212 
potent response to benzyl cinnamate (Fig. 2c), which was then used for further mechanistic studies.  213 
Detailed testing of BC2 and CD8-2 activation by benzyl cinnamate confirmed the dose-dependence, 214 
CD1a-dependence and TCR-specificity of the T cell response to benzyl cinnamate (Fig. 2d).  215 
Sphingomyelin, a known CD1a ligand (31), which has a bulky polar head group, did not activate T 216 
cells.  Responses to benzyl cinnamate was seen in two T cell lines, BC2 and Bgp (31). Benzyl 217 
cinnamate and benzyl benzoate were efficiently presented by plate-bound CD1a proteins after a short 218 
co-incubation, demonstrating the lack of a cellular processing requirement (Fig. 2c-d). These findings 219 
are most consistent with the formation of CD1a-benzyl cinnamate complexes as the target of T cell 220 
response. Thus, tree oils that are known to act as potent contact hypersensitivity agents also function 221 
as T cell stimulants that act via CD1a.   222 
 223 
Shared structures and size among oily antigens 224 
The dual benzyl rings present in benzyl cinnamate and benzyl benzoate (Fig. 2b) are 225 
chemically different from the alkyl chains present in most CD1-presented antigens.  However, they are 226 
strikingly similar to the dually ringed structure present in the unusual non-lipidic antigen presented by 227 
CD1d known as PPBF (22).  All three non-lipidic T cell stimulants are smaller (212-345 u) than most 228 
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previously known CD1-presented lipid antigens (~700-1500 u) (21). Prior CD1-lipid structures (21) 229 
established a widely accepted mechanism whereby the acyl chains rest inside the hydrophobic clefts 230 
of CD1 proteins, so that hydrophilic head groups protrude outside CD1 and form epitopes that 231 
specifically contact TCRs (38) (Fig. 3a). In contrast, the antigenic tree oils identified here, lack any 232 
identifiable polar group that could function as a TCR epitope (Fig. 3b). Further, the size of the carbon 233 
skeletons of benzyl benzoate and benzyl cinnamate (C14-16) were substantially smaller than other 234 
CD1 antigens (C20-40) and the estimated capacity of the CD1a cleft (~C36) (19, 39, 40).  Because 235 
tree oils are apparently too small to fill the CD1a cleft and protrude to the outer surface, we 236 
hypothesized that they might not form TCR epitopes and so function outside the main CD1 antigen 237 
display paradigm. For example, interactions within the CD1a cleft might alter the shape of CD1-lipid 238 
complexes from the inside (41). Alternatively, similar to recent studies of CD1a (31, 35) and CD1c 239 
(42), tree oils might displace endogenous lipids, like sphingomyelin, whose large head groups interfere 240 
with TCR contact with CD1a.  This emerging model is known as 'absence of interference' because 241 
carried lipids do not contact TCRs directly, but instead bind CD1 in a manner that allows direct contact 242 
between CD1 and the TCR (31, 35).    243 
 244 
Testing rings, unsaturations and molecular size 245 
The approach to testing chemical features was guided by the observation that squalene, benzyl 246 
benzoate and benzyl cinnamate have ringed or unsaturated structures that chemically constrain 247 
molecules, rendering them bulky and rigid. Using tree oils and skin oils as lead compounds (Fig. 3b) 248 
to generate a larger test panel (Figs. 3c-e, S2), we surveyed 29 structurally related molecules that 249 
differed in size, saturation, branching patterns or ringed structures. 15 compounds, including examples 250 
among branched (Fig. 3c), ringed (Fig. 3d-e) and saturated or unsaturated fatty acyl compounds (Fig. 251 
S2) were recognized.  This moderately promiscuous pattern was markedly different from T cell 252 
responses to glycolipids such as -galactosyl ceramide or glucose monomycolate, where altering a 253 
single stereocenter on the carbohydrate epitope abolished recognition (43, 44). However, not every 254 
oily substance was sufficient to activate T cells.   255 
Considering the particular chemical structures that control response, squalene is a C30 256 
polyunsaturated branched chain lipid antigen (Fig. 3b) (31). We found cross-reactivity to structurally 257 
related C20 geranylgeraniol and C23 geranylgeranylactone, as well as C15 farnesol, but not smaller 258 
geraniol-based compounds (Fig. 3c).  Farnesol response is notable because it is also a contact 259 
allergen in Truetest panel 2 (45) (Fig. 1) and so represents another link between contact allergens 260 
and CD1a antigens.  Further, considering molecules with branched and ringed structures related to 261 
benzyl cinnamate, we identified a new antigen, coenzyme Q2 (Fig. 3d). Although coenzyme Q2 has 262 
not been described as a contact allergen, idebenone, which has an identical headgroup (2,3‐263 
dimethoxy, 5‐methyl, 1,4‐benzoquinone), but a less hydrophobic lipid tail, comprised of a 10 carbon 264 
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alkyl chain with a hydroxyl group, is  a well known skin allergen (46-48). Also, in our CD1a plate assays, 265 
Idebenone stimulated a dose-dependent T cell response, supporting a link between coenzyme Q2-266 
related structures and contact allergens (Fig. S3). Notably, vitamin E, a known skin allergen, did not 267 
induce a response in this BC2-based screening. However, this does not exclude the existence of 268 
CD1a-restricted T cells to this hydrophobic compound within a polyclonal T cell repertoire.   269 
The identification of a strong stimulatory response to coenzyme Q2 prompted screening of 270 
coenzyme Q length analogs, finding optimal response to coenzyme Q2 but not larger or smaller chain 271 
length analogs (Fig. 3e). (Fig. 3d).   Last, comparison of 12 fatty acyl analogs consistently showed 272 
stronger response when the normally charged carboxylate group was capped by a methyl, alkyl or 273 
other structure to generate a non-polar molecule (Fig. S2).   A weak effect was seen in some cases, 274 
where potency was increased by cis-unsaturation.  275 
In summary, compared to highly flexible lipids with saturated alkyl chains, an unsaturation, 276 
ringed or branched structure correlated with higher response.  However, very highly constrained or 277 
bulky structures, such as vitamin A, vitamin D and vitamin E, were not recognized.  Considering 278 
molecular size, response was optimal with compounds (222-410 u, C15-C30), which were near the 279 
middle of the size range tested (154-862 mu, C9-C59) (Fig. 3f).  These optima were considerably 280 
smaller than known CD1 antigens (~700-1500 u).  Even the largest stimulatory compound, squalene 281 
(C30, 410 u), was substantially smaller than the predicted number of methylene units (~C36) or that 282 
would fill the CD1a cleft (1650 Å3) (19, 40). Unlike molecules that form antigenic epitopes for TCRs, 283 
no single molecular variant could be assigned as essential for T cell activation.  284 
Last, to determine if the identified link between CD1a and contact allergens is generalizable to 285 
polyclonal T cells and among genetically unrelated human donors, we screened purified polyclonal T 286 
cells (CD4+ and CD4-) from blood bank donors, and determined their response to plate-bound CD1a 287 
pre-loaded with either farnesol or coenzyme Q2.  As also seen in clinical evaluation of contact 288 
dermatitis patients, not all patients respond to every antigen, but we observed polyclonal responses 289 
to both antigens in two or more subjects using sensitive real-time qPCR testing of IFN-  response 290 
(Fig. 3g). Responses were seen in the CD4+ T cell fractions, but were stronger in the CD4-negative 291 
T cell fraction (Fig. 3g). This suggests that the normal T cell repertoire contains T cells that respond 292 
to CD1a-contact allergen complexes. Similarly, in a different set of donors, T cell responses were 293 
detected to benzyl cinnamate loaded CD1a (Fig.S4). Together, these results support the broader 294 
relevance of these CD1a allergens beyond the specificity of two T cell lines.  295 
 296 
 297 
CD1a-lipid binding to the TCR 298 
 Farnesol is a common additive to cosmetics and skin creams, where its use requires precaution 299 
labeling, based on its recognized role as a contact allergen (45).  Farnesol testing is routine in clinical 300 
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practice, where it is present in the 'fragrance mix 2' in Truetest patches.  Farnesol can also be tested 301 
as a pure compound, generating responses in ~1 % of people with suspected contact dermatitis (45).  302 
After the screen identified a farnesol response (Fig. 3c), we observed reproducible and dose-303 
dependent response for BC2 in the CD1a-coated plate assay (Fig. 4a).  Thus, farnesol was unlikely 304 
to be modified prior to recognition and was likely recognized by the BC2 TCR as a CD1a-farnesol 305 
complex.    306 
 To test this hypothesis, we loaded farnesol onto biotinylated CD1a monomers, generated 307 
fluorescent tetramers and stained the BC2 T cell line and a control line.  In several attempts with 308 
differing protocols, we failed to detect staining with CD1a-farnesol tetramers above background levels 309 
seen with farnesol-treated CD1b tetramers (Fig. S5).   Turning to surface plasmon resonance (SPR), 310 
we produced the BC2 TCR heterodimer in vitro and measured binding to untreated CD1a carrying 311 
mixed endogenous lipids (CD1a-endo), CD1a that was treated with media (CD1a-mock) and CD1a 312 
treated with farnesol (CD1a-farnesol) were coupled to SPR chips. The BC2 TCR bound to all three 313 
complexes with low but measurable binding affinities for CD1a-endo (KD = 123 M), CD1a-mock (KD 314 
= 144 M) and CD1a-farnesol (KD = 123 M) (Fig. 4b).  SPR is known to be more sensitive that 315 
tetramer staining (49), so the relatively low affinity interactions likely explained the absent tetramer 316 
staining. Yet, interactions are still in the physiological range, demonstrating direct binding between the 317 
BC2 TCR and CD1a.   However, the cross reactivity of the BC2 TCR to three forms of CD1a left 318 
unclear the role of farnesol or other carried lipids in mediating CD1a-TCR interactions.  319 
 320 
Lipid analysis of CD1a-lipid complexes 321 
 A recently proposed but unproven hypothesis is small hydrophobic lipids could fully sequester 322 
within CD1a (31, 50), displacing larger endogenous self lipids that cover TCR epitopes on the outer 323 
surface of CD1a. Therefore, we undertook direct biochemical analysis of CD1a-lipid complexes formed 324 
in vitro with detergents and stimulatory substances, analyzing elutable lipids using high performance 325 
liquid chromatography-mass spectrometry (HPLC-MS). First, we addressed the trivial possibility that 326 
the lack of effect of farnesol treatment on TCR binding to CD1a resulted from the lack of farnesol 327 
loading onto CD1a. Analysis of eluents from farnesol-treated CD1a monomers was initially 328 
inconclusive because farnesol is a non-polar alcohol and does not readily adduct the cations or anions 329 
needed for MS detection.  However, building on the fortuitous detection of a positively charged 330 
dehydration fragment [M-H20+H]+ generated in the MS source (31), we could reliably detect the 331 
equivalent product (m/z 205.196, C15H25+) from a farnesol standard.  Subsequently we detected 332 
strong signal for this product from farnesol-treated CD1a proteins but not CD1a-endo, directly 333 
documenting farnesol in CD1a complexes (Fig. 4d).   334 
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 Further, the HPLC-MS-based platform allowed broader analysis of the lipid ligands carried in 335 
CD1a-endo and CD1a-farnesol complexes.  Similar to prior reports (31, 35), we could detect many 336 
ions in CD1a-endo eluents, which were self lipids captured during protein expression in cells.   337 
Focusing on specific classes of lipids, including neutral lipids, phospholipids and sphingolipids, we 338 
could identify many self-ligands. CD1a-endo complexes carried at least three molecular species of 339 
diacylglycerol (DAG), six phosphatidylcholines (PC), six sphingomyelins (SM) and two 340 
phosphatidylinositol species. Initially these identifications were based on the expected early (DAG) or 341 
later (PI, PC, SM) retention time, as well as match of the detected m/z value with the expected mass 342 
of these ligands (Fig.  4e-f).  For one lead compound in each class, we confirmed the identification 343 
using collision-induced dissociation mass spectrometry (CID-MS), which demonstrated the 344 
characteristic phosphocholine, phosphoinositol, sphingolipid or diacylglycerol fragments (Fig. 4g).  345 
 Elution analysis of farnesol-treated CD1a directly demonstrated farnesol loading (Fig. 4d). The 346 
comparison of CD1a-endo and CD1a-farnesol eluents, showed complete or nearly complete 347 
suppression of ion chromatogram signals corresponding to all the 17 tested self-lipids (Fig. 4e, blue). 348 
Although the conditions used to load farnesol in vitro are not the same as those in immunological 349 
assays, these findings suggest high occupancy of CD1a proteins by farnesol and that farnesol and 350 
self lipids are not simultaneously bound.  Together these data support a simple model for the cross-351 
reactivity, where the TCR binds CD1a carrying either farnesol or certain self lipids that permit 352 
recognition.  Treatment of CD1a with farnesol displaces lipids with hydrophilic head groups to 353 
generated more homogenously liganded CD1a proteins (Fig. 4d-e).  354 
 355 
 356 
CD1a-farnesol crystal structure overview 357 
 To determine the structural basis of farnesol response, we solved the CD1a-farnesol crystal 358 
structure at 2.2 Å resolution (Table S1).  The electron density for the bound farnesol and surrounding 359 
CD1a residues were unambiguous (Fig. S6), allowing determination of the position and orientation of 360 
farnesol within the cleft (Fig. 5a-b). Unlike covalent binding of vitamin B metabolites to MR1 (51) and 361 
the predictions of haptenation models, we find no evidence for haptenation of CD1a residues by 362 
farnesol.   363 
 Instead the striking finding is that farnesol is sequestered deeply within the CD1a cleft, where 364 
it is fully inaccessible to TCRs. Most known amphipathic membrane lipids, such as sulfatide or 365 
sphingomyelin (19), occupy nearly all of the CD1a cleft and then extend their head groups through a 366 
portal (F'-portal) onto the external surface of CD1a (Fig. 5c).  In contrast, farnesol occupies only 36% 367 
of the cleft.  Accordingly, this relatively small ligand could have been seated in many ways within the 368 
larger cavity or potentially bound with lipid:CD1 stoichiometry of 2:1 or 3:1 (52). Instead, a preferred 369 
seating and orientation of a single molecule is observed at the junction of the A' and F' pockets.  Unlike 370 
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CD1b structures in which two lipids bind simultaneously within the cleft (53, 54), electron density 371 
corresponding to a second lipid or spacer in the cleft was not observed (Fig. 5a-b).  This finding agreed 372 
with elution experiments showing substantial exclusion of the measured self-lipids from CD1a 373 
complexes (Fig. 4e).  Together, the biochemical and structural data indicated that farnesol itself was 374 
sufficient to stabilize a partially occupied CD1a cleft.  375 
 376 
Farnesol is buried fully within CD1a 377 
 In previously solved CD1a structures in complex with oleic acid (35) or an acyl-peptide (40), 378 
the flexible fatty acyl chains take a C-shaped conformation around the margin of the curved A' pocket 379 
(Fig. 5d) (19, 35, 40).  These lipids encircle a vertical structure known as the A'  pole, which is formed 380 
by an interaction of Phe70 and Val12, located in the ceiling and floor of the A 'pocket, respectively 381 
(Fig. 5b, inset) (19, 35, 40).  The semi-rigid and branched structure of farnesol does not allow the C-382 
shaped peripheral conformation seen with other lipids and instead lies in the center of the A' pocket, 383 
disrupting the A’ pole.  The orientation of farnesol is discernable: the terminal methyl and hydroxyl 384 
groups point towards the A’ and F’ pocket, respectively (Fig. 5b).  The polar hydroxyl group situated 385 
nearer the solvent-exposed F’ portal of CD1a with ~ 15 percent of its surface water exposed. Farnesol 386 
made van der Waals contacts with Phe10, Trp14, Phe70, Val98, Leu161, Leu162 and Phe169 from 387 
CD1a. (Fig. 5b, Table S2).  Here, Trp14 stacked against the unsaturated hydrocarbons C12 and C14 388 
of farnesol, stabilizing further the bound lipid within the cleft. Interestingly, the same Trp14 residue 389 
maintains hydrophobic contacts with sphingosine and acyl chain moieties in the CD1a-sphingomyelin 390 
and CD1a-sulfatide structures (19), respectively.  Collectively, this positioning mechanism appears to 391 
be driven by unsaturations in farnesol, which limit its ability to bend and provide and van der Waals 392 
interactions with the inner surface of CD1a.   393 
 Parallels in the positioning of CD1a-urushiol and CD1a-farnesol (Fig. 5e) highlight how bulky 394 
and constrained lipids positioning differ from the seating of acyl chain containing ligands (Fig. 5d). 395 
Although farnesol and urushiol are not located in the same position, they are both situated near the 396 
junction of the A' and F' pockets (Fig. 5e) and do not take the deep and curved positioning at the rim 397 
of the A' toroid (Fig. 5d). Whereas oleate and acyl peptide wrap around the intact A' pole (Fig 5d, 5b 398 
inset), farnesol and urushiol complexes show a marked repositioning of Phe 70, which disrupts the A' 399 
pole (Fig. 5b, e). Urushiol extends substantially into the F'-pocket so that it approaches the F' portal 400 
of CD1a.  It is unknown whether TCRs contact urushiol, but the molecule is adjacent to the surface 401 
portal (30) and TCRs can contact lipids located just within the portal (55).   In contrast, farnesol is ~ 402 
8Å more deeply positioned, so that it is unequivocally separated from the F' portal and the TCR contact 403 
surface (Fig. 5e).  404 
 Overall, the structure-activity relationships (Fig. 3) indicated that many small, hydrophobic, 405 
bulky lipids from consumer goods are recognized by T cells. The biochemical (Fig. 4) and structural 406 
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(Fig. 5) analysis of CD1a-lipid complexes demonstrate that farnesol's small size and unsaturated 407 
structure allow it to interact specifically, but not covalently, within CD1a.  This binding interaction 408 
stabilizes the CD1a cleft and positions farnesol out of the reach of the TCR, largely or fully displacing 409 
lipids that normally emerge to the outer surface of CD1a (19, 35, 40).    410 
 411 
Discussion  412 
 In 1963 Gell and Coombs classified human disease-related immune manifestations into 4 types 413 
of hypersensitivity reactions (3).   Despite the early development and descriptive nature of this scheme, 414 
the classification system is still widely taught in clinical immunology and medicine.  Type I, II and III 415 
reactions are rapid and mediated by B cells, whereas the delayed Type IV response is mediated by T 416 
cells.  Our study sought molecular mechanisms underpinning Type IV hypersensitivity to the most 417 
common contact dermatitis allergens in consumer products.  Our data provide specific molecular 418 
connections between CD1a-reactive T cells and four structurally related contact dermatitis allergens: 419 
benzyl benzoate, benzyl cinnamate, farnesol and coenzyme Q related compounds. Whereas haptens 420 
(9), drugs (7), or cations (8) can influence MHC-peptide display, here we detail a straightforward 421 
mechanism for T cell activation by small molecules that non-covalently bind CD1a.  422 
 In the MHC and CD1 systems, the most common recognition mechanism involves TCR co-423 
contact with an epitope on the carried peptide or lipid and the antigen presenting molecule (21, 56-424 
58). Here we show evidence that the key active components of balsam of Peru and farnesol activate 425 
T cells by binding to CD1a without cellular processing.  However, both the structural and biochemical 426 
data strongly point to a new model of recognition that does not involve TCR contact with epitopes 427 
present on the stimulatory small molecules.  Antigenic tree oils, PPBF, farnesol, coenzyme Q and the 428 
other 14 oily stimulants identified here all lack carbohydrate, phosphate or peptidic groups that 429 
normally serve as TCR epitopes. We show that the BC2 TCR can cross-react among at least 16 430 
stimulatory compounds, which do not share any single chemical structure that would be a candidate 431 
cross-reactive epitope. More conclusively, farnesol resides deeply within the CD1a cleft, essentially 432 
ruling out direct contact with the TCR.  Sequestration of molecules of a small size is could be a general 433 
mechanism of their recognition, since all of the stimulatory molecules are smaller than the CD1a cleft 434 
(21, 40, 57).  435 
 Prior studies of CD1-lipid complexes have emphasized head group positioning, where the 436 
seating of amphipathic lipids in the cleft is guided by carbohydrates or charged moieties that interact 437 
near the F' portal. Alkyl chains have a ‘bland’ repetitive structure, and have been described as sliding 438 
within CD1 allowing diversely positioning in the groove (54, 59).  Based on this concept, we expected 439 
that the small hydrophobic ligands studied here might slide freely or adopt multiple positions in the 440 
CD1a cleft. Also, since many of the lipids have a molecular size that is less than half the volume of the 441 
CD1a cleft, they might have bound in pairs or together with spacer lipids (52, 53, 60, 61).  However, 442 
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farnesol shows one defined position in the CD1a groove.  Both mass spectrometry and 443 
crystallographic analysis failed to detect co-binding spacer lipids indicating that partial occupancy by 444 
one small lipid is sufficient to stabilize the CD1a cleft.  445 
 Comparison of CD1a-farnesol with previously solved CD1a-lipid structures provides insight into 446 
the roles of steric hindrance and interior pocket remodeling. CD1a-oleate (35), CD1a-mycobactin-like 447 
lipopeptide (40), CD1a-sulfatide (19) and CD1a-sphingomyelin (35)  complexes involve lipids with 448 
flexible alkyl chains.  These alkyl chains insert deeply into CD1a by curling along the outer wall of the 449 
A' pocket and wrapping around the A' pole to insert fully within the cleft (40). In contrast farnesol is 450 
chemically hindered and bulky, based on polyunsaturation and methyl branching.  The rigid and bulky 451 
moiety in urushiol derives from a substituted catechol ring. These two molecules cannot curl to trace 452 
the outer wall of the A' pocket so do not penetrate deeply, and both sit in a central position within the 453 
A' pocket that prevents the A' pole form forming. Farnesol is anchored in a specific by a series of Van 454 
der Waals interactions with named pocket residues formed by its polyunsaturated and branched 455 
structure.  While the roles of benzyl rings in benzyl benzoate and benzyl cinnamate are not studied 456 
structurally, they also constrain the chemical structure in ways that are also expected to prevent the 457 
side-wall curvature (19, 35, 40).  More generally, many of the stimulatory lipids identified here and in 458 
a recent study (31), including farnesol, squalene, geranylgeraniol, geranylgeranylacetone and 459 
coenzyme Q are polyunsaturated or branched isoprenoid lipids that could plausibly anchor in CD1a 460 
by similar mechanisms.  461 
 Binding wholly within CD1a could trigger T cell response by remodeling the 3-dimensional 462 
structure of CD1a, as previously reported for CD1d (62, 63), CD1b (54) and CD1c (41, 64).  However, 463 
comparing CD1a-farnesol with all CD1a-lipid structures solved to date (19, 35, 40) does not 464 
demonstrate a broad or obvious change in CD1a conformation.  Also, binding of the BC2 TCR to both 465 
CD1a-farnesol and CD1a-endo point away from this explanation. Instead, biochemical analysis of 466 
CD1a-endo complexes and the CD1a-farnesol structure both indicate that farnesol displaces 467 
endogenous ligands from the cleft.  Whereas farnesol can be considered a headless ligand, some 468 
amphipathic self lipid ligands in CD1a-endo structures have head groups comprised of phosphates or 469 
sugars that normally cover the exposed surface of CD1a (35).  In the case of the sphingomyelin, it 470 
blocks autoreactive T cells by interfering with TCR contact with CD1a (31, 35).  Our experimental 471 
observations rule in key aspects of the absence of interference model, where activating substances 472 
are sequestered within the CD1a cleft, so that recognition occurs by ejecting self lipids and freeing up 473 
epitopes on the surface of CD1a itself.  474 
 As contrasted with MHC I and MHC II, where peptides are broadly exposed over the lateral 475 
dimension of the platform, human CD1 proteins have a large roof-like structure above their clefts and 476 
a small antigen exit portal at the margin of the platform (65). This creates a potentially large, ligand-477 
free TCR contact surface on CD1 proteins.  Evidence for the predominant contact of α  TCRs with the 478 
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surface of CD1 proteins in preference to carried lipids, including the extreme case in which TCRs 479 
contact CD1 only, is becoming a central theme in CD1 research (65).  Recent studies have shown 480 
direct TCR contact with the unliganded surface of CD1a and CD1c by autoreactive clones and 481 
polyclonal T cells (31, 35, 42).  Thus, the stimulatory compounds identified here, which are small and 482 
internally sequestered, provide a molecular link to polyclonal autoreactive T cell responses, which are 483 
specific for the surface of CD1 rather than the carried lipid.  484 
The presence of CD1a in all individuals prompts the question why allergic contact dermatitis 485 
does not universally develop in everyone. However, inter-individual differences that may play a role 486 
include permeability of the skin barrier (66), dose and number of chemical exposures to allergens, 487 
regulatory T cell activity (67-69), and inter-individual differences in T cell repertoires.  Prior studies 488 
show that there is inter-individual variability in the frequency of CD1a-restricted T cells in the blood 489 
and skin of healthy individuals, and differences CD1a autoreactive response rates in skin (25, 66, 70, 490 
71). Increased CD1a-restricted T cells responses were observed in allergic individuals and those with 491 
inflammatory skin disease (66, 70, 72), which may be a factor in susceptibility to development of CD1a-492 
mediated allergic contact dermatitis in certain individuals.   Consistent with these known patterns of 493 
antigen response, our small study of 11 humans demonstrates differing patterns of polyclonal 494 
response in each individual rather than a universal response to one antigen, which might be expected 495 
from an innate receptor. 496 
 Overall, the molecular analysis of tree oils and isoprenoid lipids presented in this manuscript 497 
invites focused consideration of the role of CD1a in T cell mediated skin diseases.  In this new view, 498 
the pattern of high density CD1a on the Langerhans cell network present throughout the skin could 499 
mediate responses to oils naturally produced within the skin or oils that contact the skin through 500 
application of commercial skin products containing botanical extracts, synthetic lipids or oils.  Other 501 
immunogenic oils used in human patients or for experimental biology include the adjuvant MF-59 502 
(squalene) and incomplete Freund's adjuvant (mineral oil).  These immunogens, as well as drug-like 503 
small molecules resembling PPBF or sulfonamide antibiotics, could plausibly act through the CD1 504 
system.     505 
 506 
 507 
  508 
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Materials and Methods 509 
 510 
Contact dermatitis antigen screen 511 
The T.R.U.E. (Thin-layer Rapid Use Epicutaneous Patch) test 1 (Truetest 1) is a test routinely used in 512 
clinic to diagnosis contact dermatitis in response to the most common allergens (SmartPractice, 513 
Phoenix, AZ). The system consists of surgical tape (5.2 x 13.0 cm) that is embedded with antigen 514 
patches of 0.81 cm2 with each coated with a polyester film that contains uniformly dispersed specific 515 
allergen. Using sterile technique, individual allergen patches were cut and placed directly in the assay 516 
wells containing ~ 106 antigen presenting cells and 1 ml T cell media in 24 well plates (contact method) 517 
or first extracted by soaking patch in 1 ml media (2 hrs, 37°C), followed by removing the patch and 518 
transferring 100 L of media to T cell assays.   Antigen dose was normalized to mm2 of patch exposure.  519 
Antigens or extracts were co-cultured with 50,000 CD1a-transfected or mock-transfected K562 cells 520 
(25) and a CD1a-dependent T cell lines in a 96 well plate.  Activation was measured by IFN-gamma 521 
ELISA (Enzyme-linked immunosorbant assay, Thermo Scientific). 522 
 523 
CD1a assays for T cell antigens 524 
Balsam of Peru, balsam of Peru oil, benzyl cinnamate, and benzyl benzoate or other isolated antigens 525 
were dried in clean glass, subjected to water bath sonication in T cell media for 120 sec and cultured 526 
with 50,000 CD1a-transfected K562 cells or mock-transfected K562 cells for 3 h at 37°C and then co-527 
cultured with 50,000-200,000 cells per well of an autoreactive T cell line (BC2, Bgp) (31) or foreign 528 
antigen reactive T cells (CD8-2) (18) for 24 h at 37°C in 96 well plates as previously described (31). 529 
Activation was measured using IFN-gamma ELISA (Thermo Scientific). For blocking experiments, 530 
CD1a-transfected K562 cells were pre-incubated for 1 h at 37°C with CD1a blocking antibody (OKT-531 
6) or isotype-matched control IgG (Pγ) (10 μg/ml) before the addition of T cells. For plate assays, 96-532 
well streptavidin plates (Thermo Scientific) were incubated for 24 h at room temperature with 533 
biotinylated CD1a or CD1b protein (10 μg/ml, NIH Tetramer Core Facility) and anti-CD11a (β.5 μg/ml) 534 
in PBS, pH 7.4 as previously described (31). For the acid-stripping protocol (Fig. 4, Fig. 5a, and 535 
supplemental Fig. 2), after 24 h of coating with protein, plates were washed three times with PBS, 536 
followed by washing twice with citrate buffer at a pH of 3.4 for 10 min, followed three washes in PBS 537 
before the addition of lipid antigens (30). Polyclonal T cell assays were performed using FACS sorted 538 
T cells from PBMC (CD4- and CD4+), and CD1a coated 96-well plates as described above. Plate-539 
coated CD1a was either treated with buffer only (0.05% CHAPS in PBS) or lipid antigens sonicated in 540 
buffer and incubated overnight at 37°C. Plates were washed three times and then purified T cells were 541 
added to the wells and incubated overnight at 37°C. RNA was extracted using Rneasy (Qiagen), and 542 
first-strand cDNA synthesis was performed using iScript (BioRad).  543 
 544 
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Lipid sources 545 
Balsam of Peru (W211613), balsam of Peru oil (W211710), benzyl cinnamate (234214), benzyl 546 
benzoate (B9550), geranylgeraniol (G3278), farnesol (277541), geranylgeranyl acetone (G5048), 547 
geraniol (163333), squalene (S3626), geranyl acetone (250716), vitamin K1 (V3501), vitamin K2 548 
(V9378), vitamin A (R7632), vitamin E (T3251), vitamin D3 (C9756), coenzyme Q2 (C8081), coenzyme 549 
Q0 (D9150), coenzyme Q4 (C2470), coenzyme Q6 (C9504), coenzyme Q10 (C9538), palmitoleic acid 550 
(P9417); methyl palmitoleate (P9667); cis-11-hexadecenal (249084), palmityl acetate (P0260), 551 
palmitoleyl alcohol (P1547), lauryl palmitoleate (P1642), oleamide (O2136), palmitoyl ethanolamide 552 
(P0359), tetradecanoic acid ethylamide (R425567), N-oleoyl glycin (O9762), N,N-dimethyl 553 
tetradecanamide (S347388), 1-dodecyl-2-pyrrolidinone (335673) were obtained from Sigma-Aldrich 554 
(St. Louis, MO). Q1 was obtained from (270-294-M002) Alexis Biochemicals.  555 
 556 
Lipid analysis by TLC 557 
Silica-coated glass thin layer chromatography (TLC) plates (10 cm x 20 cm; Scientific Adsorbents 558 
Incorporated) were pre-cleared in chloroform-methanol-water (60:30:6; vol/vol/vol). Samples (10 - 20 559 
μg) were developed with a solvent system-hexane/diethyl ether/acetic acid (70/30/1 (vol/vol/vol)). For 560 
visualization, plates were sprayed with a solution of 3% (wt/vol) of cupric acetate in 8% (vol/vol) 561 
phosphoric acid, followed by heating for 20-30 min at 150 °C. 562 
 563 
Nanoelectrospray-ionization Mass Spectrometry 564 
β μg/ml of methanol solution was prepared for each reagent, and then 10 μl was loaded onto a glass 565 
nanospray tip for positive-mode electrospray-ionization mass spectrometry performed on a LXQ 566 
(Thermo), two-dimensional ion-trap mass spectrometer. The spray voltage and capillary temperature 567 
were set to 0.8 kV and 200 °C.  568 
 569 
High performance liquid chromatography (HPLC)-QTof-Mass spectrometry 570 
CD1a-endo (200 µg) and CD1a-farnesol (200 µg) were transferred to 15-ml glass tubes and treated 571 
with chloroform, methanol, and water for lipid extraction according to the method of Bligh and Dyer 572 
(73).  The lipid-containing organic solvent layer was separated from the top aqueous layer by 573 
centrifugation at 850 g for 10 min. For HPLC-MS analysis, the samples were normalized based on the 574 
input proteins (20 µM), and β0 µl of eluent was injected to an Agilent 6530 Accurate-Mass Q-TOF 575 
spectrometer equipped with a 1260 series HPLC system using a normal phase Inertsil diol column 576 
(150 mm × β.1 mm, γ micron, GL Sciences) with a guard column (10 mm x γ mm, γ micron, GL 577 
Sciences), running at 0.15 ml/min according to a published method (74).  578 
 579 
CD1a recombinant expression and purification 580 
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The glycoprotein CD1a was expressed in HEK293S GnTI- cells and purified as previously described 581 
(35). Following an endoglycosidase H (New England BioLabs) and thrombin treatment, the purified 582 
CD1a was first loaded with the ganglioside GD3 (GD3) (Avanti) that was dissolved in a solution 583 
containing 2.5% dimethylsulfoxide (DMSO) and 0.5% tyloxapol (Sigma). CD1a was first incubated with 584 
GD3 overnight at room temperature at a molar ratio of 1:8. The CD1a sample loaded with GD3 was 585 
further purified using ion exchange chromatography (MonoQ 10/100 GL-GE Healthcare). Trans, trans-586 
farnesol (Sigma) was dissolved in a solution containing 2.5% DMSO and 0.5% tyloxapol (Sigma). The 587 
CD1a-GD3 sample was then incubated overnight with farnesol at a 1:100 molar ratio and at room 588 
temperature. A subsequent ion exchange chromatography (MonoQ 10/100 GL) was performed to 589 
remove the excess of farnesol, CD1a-GD3 and tyloxapol. 590 
Expression, refolding and purification of recombinant TCRs 591 
The BC2 TCR was produced using a previously described method (31). Briefly, individual α and  592 
chains of the TCR, with an engineered disulfide bond between the TRAC and TRBC constant domains, 593 
were expressed in BL21 E. coli cells as inclusion bodies and solubilised in 8 M urea buffer containing 594 
10 mM Tris-HCl pH 8, 0.5 mM Na-EDTA, and 1 mM dithiothreitol. The TCR was then refolded in buffer 595 
that was comprised of 5M urea, 100 mM Tris-HCl pH 8, 2 mM Na-EDTA, 400 mM L-Arg-HCl, 0.5 mM 596 
oxidized glutathione and 5 mM reduced glutathione. The refolded solution was dialyzed twice against 597 
10 mM Tris-HCl pH 8.0 overnight. The dialyzed samples were then purified through DEAE cellulose, 598 
size-exclusion and anion exchange HiTrap Q chromatography approaches. The quality and purity of 599 
the samples were analyzed via SDS-PAGE. 600 
Crystallization, structure determination and refinement 601 
Seeds obtained from previous binary CD1a-antigen crystals (30) were used to grow crystals of the 602 
CD1a-farnesol binary complex in 20-25% PEG 1500 / 10% MMT buffer pH 5-6. The crystals were 603 
flash-frozen and data were collected at the MX2 beamline (Australian Synchrotron) to a 2.2 Å 604 
resolution. All the data were processed with the program XDS (75) and were scaled with SCALA from 605 
the CCP4 programs suite (76). Upon successful phasing by molecular replacement using the program 606 
PHASER (77) and the CD1a-urushiol structure as search model (30), the farnesol electron density 607 
was clearly evident in the unbiased electron density maps in addition to some very weak residual 608 
density. An initial run of rigid body refinement was performed using phenix.refine (78). Iterative model 609 
improvement was performed using with the program COOT (79) and phenix.refine. The final 610 
refinement led to an R/R-free (%) of 20/25. The quality of the structure was confirmed at the Research 611 
Collaboratory for Structural Bioinformatics Protein Data Bank Data Validation and Deposition Services 612 
website. All presentations of molecular graphics were created with UCSF-Chimera (80).  613 
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 614 
Surface Plasmon resonance 615 
Biotinylated CD1a-endogenous lipids derived from HEK293 cells was incubated over-night with 30-616 
fold molar excess of farnesol solubilized in 2.5% dimethylsulfoxide/0.5% tyloxapol (CD1a-farnesol) or 617 
with solvent only (CD1a-mock). The sample was coupled onto research-grade streptavidin-coated 618 
chips (SA) to a mass concentration of ~3000 resonance units (RU). Increasing concentrations of the 619 
BC2 TCR (0–β00 μM) were injected over all flow cells for γ0s at a rate of 5 μl/min on a Biacore γ000 620 
in 10 mM Tris-HCl pH 8, 150 mM NaCl buffer. The final response was calculated by subtraction of the 621 
response for CD1a-endogenous minus a flow cell containing an unrelated protein. The data were fitted 622 
to a 1:1 Langmuir binding model using BIAevaluation version 3.1 software (Biacore AB) and the 623 
equilibrium data analyzed using Prism program for biostatistics, curve fitting and scientific graphing 624 
(GraphPad). 625 
 626 
Statistical analyses 627 
All statistical analyses were performed in R (https://www.R-project.org/). Pairwise t tests, ANOVA, post 628 
testing and adjustments of p values for multiple hypothesis testing used base R and the package 629 
emmeans (https://CRAN.R-project.org/package=emmeans).  Dose response analyses used the 630 
package drc to fit log normal or logistic curves to the data and to test fitted models against simplified, 631 
pooled models (81).  Raw data and R code are available on request.  632 
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Figure Legends 633 
 634 
 635 
Figure 1.  Balsam of Peru activates T cells via a CD1a-dependent, APC-independent 636 
mechanism. T cell lines with  CD1a autoreactivity (BC2, Bgp) or foreign antigen reactivity (CD8-2) 637 
were tested for activation to lipids using IFN- ELISA in cellular assays with CD1a-transfected K562 638 
cells (K562-CD1a) or mock transfected K562 cells (K562-mock) (a, b, e) or on streptavidin plates 639 
coated with biotinylated CD1 proteins (c, d). Data are representative of three or more experiments 640 
each with the mean of triplicate measurements shown with standard deviation. The significance of lipid 641 
concentration on IFN-gamma release was tested by one-way ANOVA (panel a, c). Relevant pairwise 642 
comparisons were tested using Welch’s t-test (panel b). Post-hoc comparison of marginal means after 643 
adjustment by the Sidak method was used to group treatments at the specified significance level 644 
following a significant result by two-way ANOVA (panel d). Post-hoc comparison by least-squares 645 
means after adjustment by the Sidak method was used to group treatments with non-overlapping 646 
marginal means and 95% confidence levels into a, b or c at the specified significance level following 647 
a significant result by two-way ANOVA (panel e). 648 
 649 
Figure 2.  Chemical analysis of antigenic substances in balsam of Peru.   a.  Normal phase silica 650 
TLC plate resolves balsam of Peru oil (BPO), crude balsam of Peru (BP), synthetic benzyl cinnamate 651 
(BC) and synthetic benzyl benzoate (BB).  b. Structures of benzyl cinnamate and benzyl benzoate are 652 
shown with the expected mass of sodium adducts [M+Na]+, which were detected in positive-mode 653 
nanoelectrospray ionization mass spectrometry.  c. T cell clones that are autoreactive to CD1a (BC2) 654 
or foreign antigen (CD8-2) were tested for response to antigens (g/ml) or sphingomyelin (sphingomy) 655 
by IFN- ELISA in cellular (e) or CD1a-coated plate (c, d) assays. Data are representative of three or 656 
more experiments, each shown as the mean of triplicate samples +/- standard deviation. The 657 
significance of lipid concentration on interferon gamma release was tested by one-way ANOVA (panel 658 
c) The significance of benzyl cinnamate and benzyl benzoate concentration on interferon gamma 659 
release and of the effects of CD1b or CD8-2 T-cells were tested by two-way ANOVA (panels d,e). 660 
 661 
Figure 3. T cell responses to chemically diverse oily substances.  a. Using phosphatidylcholine 662 
as an example, CD1 ligands are comprised of head groups and lipid anchors.  b.  BC2 T cells were 663 
tested for cytokine release in response to small hydrophobic molecules pulsed on plate-bound CD1a 664 
pre-treated with acidic citrate buffer to strip ligands (31). Tested compounds are classified into groups 665 
based on the presence of branched chain unsaturated lipids structurally related to squalene (c), ringed 666 
lipids structurally related to benzyl cinnamate (d) or molecules that show branched, polyunsaturated 667 
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and ringed structure, such as coenzyme Q2 (e).  Results of triplicate analyses are shown as mean +/- 668 
standard deviation with each compound tested 2 or more times. Post-hoc comparison by marginal 669 
means of the interaction term between lipid and concentration after adjustment by the Sidak method 670 
was used to group treatments by non-overlapping 95% confidence levels at the specified significance 671 
level following a significant result by two-way ANOVA. f. The size of all tested antigens is shown based 672 
on the number of carbon atoms (C) or mass (u), as compared to the volume of the CD1a cleft, which 673 
has been measured at 1650 Å3, and can accommodate ~ 36 methylene units (C36) (19, 40). g. Purified 674 
T cells (CD4- and CD4+) were incubated overnight with plate-bound CD1a, either mock treated or pre-675 
treated with the indicated antigens (50µg/ml). Real-time PCR of IFN-gamma mRNA relative to -actin.* 676 
P<0.05 student t-test 2-sided, antigen-treated compared to mock-treated CD1a. 677 
 678 
Figure 4.  CD1a-farnesol complexes. a. IFN- release by BC2 T cells in response to CD1a-coated 679 
plates treated with farnesol was measured. * The significance of lipid concentration on interferon 680 
gamma release was assessed by marginal means with adjustment by the Sidak method after a 681 
significant result by ANOVA, treating experiments 1 and 2 as blocks. At the highest concentration of 682 
farnesol in both experiments, non-overlapping 95% confidence intervals were observed at p < 0.001 683 
b. Affinity measurements (KD) by surface plasmon resonance in response to the recombinant BC2 684 
TCR binding biotinylated CD1a directly isolated from cells (CD1a-endo), CD1a pre-treated with 685 
farnesol (CD1a-farnesol) or CD1a treated with buffer (CD1a-mock).  Positive mode HPLC-MS analysis 686 
of a farnesol standard (c) and eluents from farnesol-treated CD1a (d) demonstrated ions that matched 687 
the expected mass (m/z 205.195) of an indicated dehydration product with a retention time of 2.9 min. 688 
e-f. Lipid eluents from CD1a-endo and CD1a-farnesol were analyzed by positive normal phase HPLC-689 
MS QToF mass spectrometry.  Ion chromatograms were generated at the nominal mass values of 690 
diacylglycerol (DAG), phosphatidylcholine (PC), sphingomyelin (SM) and phosphatidylinositol (PI), 691 
which are shown as CX:Y, where X is the number of methylene units in the combined lipid chains and 692 
Y is the total number of unsaturations. g. Compound identifications were based on the unknown 693 
matching the retention time and mass of standards.  Further, one compound in the PC, SM and PI 694 
families (shown in color) underwent collision-induced dissociation mass spectrometry analysis to 695 
generate the indicated diagnostic fragments.    696 
 697 
Figure 5.  Crystal structure of CD1a-farnesol complexes. a. Overview of the binary crystal structure 698 
of CD1a (grey)-farnesol (purple)/ βm(cyan). b. Molecular interactions of farnesol (purple) with the 699 
hydrophobic residues within CD1a binding cleft (grey surface). The side chains of the residues within 700 
4 Å distance from the lipid are shown. A diagram of trans, trans farnesol with carbon numbering is 701 
shown. The A’ pole formed by V1β-F70 interaction in the context of oleic acid-bound CD1a pocket 702 
(PDB ID: 4X6D) is highlighted in the inset.  c-e. Superimposition of CD1a bound to farnesol and 703 
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sphingomyelin (PDB ID: 4X6F, (35)) (c) lipopeptide (PDB ID: 1XZ0, (40)) (d) and urushiol (PDB ID: 704 
5J1A, (30)) (e). 705 
 706 
 707 
Supplemental Figure Legends 708 
 709 
Supplemental Figure 1. Screening human T cells for responses to known contact allergens. 710 
a. The human α  T cell clone BC2 was cultured in direct contact with sterile Truetest 1 patches coated 711 
with the indicated antigen or no antigen (control patch) in the presence of K562-CD1a cells followed 712 
by -interferon ELISA.  b. Alternatively, the soaking method uses same cellular assay except that 713 
patches were pre-soaked in T cell media for 2 hrs, followed by testing supernatants for BC2 714 
stimulation.  Data are mean values with standard deviations and representative of two or more 715 
experiments. The significance of the lipid treatment versus the control patch was assessed by ANOVA 716 
after fitting curve to each treatment and testing the two-curve model against a simplified model that 717 
assumed no effect of treatment, with p values adjusted by Holm’s method (*** p<0.0001, ** p<0.005, 718 
* p<0.05) 719 
 720 
Supplemental Figure 2. CD1a-dependent T cell response to small hydrophobic molecules.  721 
BC2 T cells were tested for cytokine release by IFN-  ELISA, in response to small hydrophobic 722 
molecules pulsed on plate-bound CD1a.  Whereas molecules with a primary carboxylate or amine 723 
moiety can carry a charge at neutral pH, capping refers to the presence of any moiety covalently bound 724 
to the carboxylate or amine moiety, which removes the charge. The dose-response for each lipid was 725 
fit with a curve, parameters extracted and adjusted using simultaneous inference. * Lipids with a 726 
positive lower 95% confidence interval.   727 
 728 
Supplemental Figure 3.  Idebenone is recognized by CD1a-restricted T cell line BC2. 729 
Plate-coated recombinant CD1a was loaded with increasing concentrations of Idebenone overnight. 730 
After washing away excess lipid, CD1a-restricted T cell line (BC2) was added to plate. IL-2 release in 731 
the supernatant was measured by HT2 bioassay. The significance of lipid concentration on IL-2 732 
release was assessed by marginal means with adjustment by Tukey’s method after a significant result 733 
by one-way ANOVA. * At the highest concentration of Idebenone, non-overlapping 95% confidence 734 
intervals were observed at p < 0.0001. 735 
 736 
Supplemental Figure 4. CD1a-dependent polyclonal T cell responses to contact allergens.  737 
FACS sorted CD4- and CD4+ T cells were incubated with plate-bound CD1a, mock-treated or treated 738 
with the indicated antigens, overnight after which RNA was extracted and realtime qPCR was 739 
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performed for IFN-  (normalized to -actin). n.d. = not detected. .* P<0.05 student t-test 2-sided, 740 
antigen-treated compared to mock-treated CD1a. 741 
 742 
Supplemental Figure 5.  CD1a tetramer staining of CD1a-autoreactive T cell line.  743 
Mean fluorescence intensity of BC2 T cells stained with CD1a or CD1b tetramers carrying mixed 744 
endogenous lipids (CD1a-endo, CD1b-endo), or CD1a tetramers treated with farnesol.   745 
 746 
Supplemental Figure 6. Electron density for farnesol in CD1a-farnesol binary complex.  747 
a Unbiased difference electron map (Fo-Fc) of farnesol is contoured at β.βσ. b. The refined 2Fo-Fc 748 
map of farnesol is contoured at 1.1σ. 749 
 750 
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Supplementary Table 1.   1021 
Data collection and refinement statistics. 1022 
 CD1a-farnesol 
Temperature (K) 100 
Wavelength (Å) 0.954 
Resolution range (Å) 45.44 - 2.2 (2.27 - 2.2) 
Space group P 21 21 21 
Unit cell dimensions (Å) 
a=42.1 b=90.2 c=105.3 
===90˚ 
Total reflections 561722 (47953) 
Unique reflections 21051 (1772) 
Multiplicity 26.7 (27.1) 
Completeness (%) 100.0 (100.0) 
Mean I/sigma(I) 9.8 (3.0) 
Rp.i.m (%)1 4.3 (26.7) 
Wilson B-factor (Å2) 40.90 
Rwork (%)2 20.5 (25.9) 
Rfree (%)3 24.8 (34.8) 
Number of non-hydrogen atoms 3143 
  macromolecules 3009 
  ligands 28 
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  solvent 106 
Protein residues 374 
rmsd bonds (Å) 0.004 
rmsd angles (˚) 0.98 
Ramachandran favored (%) 97.54 
Ramachandran allowed (%) 2.46 
Ramachandran outliers (%) 0 
Average B-factor (Å2) 55.4 
  protein 55.6 
  farnesol 56.5 
  water 48.6 
Statistics for the highest-resolution shell are shown in parentheses. 1023 
1Rp.i.m = Σhkl [1/(N-1)]1/2 Σi | Ihkl, i - <Ihkl> | / Σhkl <Ihkl> 1024 
2Rwork = ( Σ | |Fo| - |Fc| | ) / ( Σ |Fo| ) - for all data except as indicated in footnote 3.  1025 
35% of data was used for the Rfree calculation 1026 
 1027 
 1028 
  1029 
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Supplementary Table 2.  1030 
 1031 
Farnesol residue CD1a residue Bond type 
C1 Leu161 VDW 
C3 Phe10, Phe169 VDW 
C5 Leu161 VDW 
C6 Gly100, Leu162 VDW 
C13 Trp14, Phe70 VDW 
 1032 
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Supplemental Figure 6, Nicolai et al. 
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